BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.

BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...

BTIG Research has recently reduced Ginkgo Bioworks Holdings Inc (DNA) stock to Sell rating, as announced on May 15, 2024, according to Finviz. Earlier, on May 10, 2024, William Blair had reduced the ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG Research has recently reduced MGM Resorts International (MGM) stock to Neutral rating, as announced on February 3, 2025, according to Finviz. Earlier, on July 3, 2024, BTIG Research had initiated ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...